Urology Times· @UrologyTimes · X·· 2 天前评分70
正文 · 原文
KEYNOTE-866 at #ESMO2026: Adding perioperative pembrolizumab to neoadjuvant cisplatin plus gemcitabine did not significantly improve event-free survival in patients with cisplatin-eligible MIBC. https://www.urologytimes.com/view/adding-perioperative-pembrolizumab-chemotherapy-does-not-improve-efs-mibc
263 浏览 · 1 赞 · 0 转发 · 0 回复
会议摘要
4735O按 Proffered paper 1: Genitourinary tumour, renal and urothelial 对上
Perioperative pembrolizumab (pembro) or placebo (pbo) + neoadjuvant cisplatin (cis) and gemcitabine (gem) in participants (pts) with muscle-invasive bladder cancer (MIBC): the double-blind, phase 3 KEYNOTE-866 study
https://esmocongress.esmo.org来源：Urology Times · x.com